BridgeBio Pharma Inc

NASDAQ:BBIO  
9.23
+0.15 (+1.65%)
Products, Regulatory

Bridgebio Pharma Shares Positive Phase 2B Data, Announces Pivotal Study Design For Phase 3 Trial Of Encaleret

Published: 06/13/2022 12:39 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (adh1).
Bridgebio Pharma Inc - Treatment With Encaleret Resulted in Rapid and Sustained Restoration of Normal Mineral Homeostasis.
Bridgebio Pharma Inc - Treatment With Encaleret Was Well-tolerated Without Any Reported Serious Adverse Events.
Bridgebio Pharma Inc - Completed End of Phase 2 Interaction With US FDA; Phase 3 Pivotal Study is Anticipated to Begin in 2022.